Global Congestive Heart Failure Drugs Market 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Therapeutic Class
08. Late Stage Pipeline Molecules
09. Geographical Segmentation
09.1 Congestive Heart Failure Drugs Market in Americas
09.1.1 Market Size and Forecast
09.2 Congestive Heart Failure Drugs Market in Europe
09.2.1 Market Size and Forecast
09.3 Congestive Heart Failure Drugs Market in Asia
09.3.1 Market Size and Forecast
09.4 Congestive Heart Failure Drugs Market in ROW
09.4.1 Market Size and Forecast
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2013
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 AstraZeneca plc
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation by Revenue 2013
18.1.4 Business Segmentation by Revenue 2011-2013
18.1.5 Sales by Geography
18.1.6 Business Strategy
18.1.7 Key Developments
18.1.8 SWOT Analysis
18.2 Bristol-Myers Squibb Co.
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Key Product Offerings
18.2.4 Revenue by Geography
18.2.5 Business Strategy
18.2.6 Key Information
18.2.7 SWOT Analysis
18.3 GlaxoSmithKline
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation
18.3.4 Business Segmentation by Revenue 2012 and 2013
18.3.5 Sales by Geography
18.3.6 Pipeline Products
18.3.7 Business Strategy
18.3.8 Key Information
18.3.9 SWOT Analysis
18.4 Merck & Co. Inc.
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation by Revenue 2013
18.4.4 Business Segmentation by Revenue 2012 and 2013
18.4.5 Sales by Geography
18.4.6 Business Strategy
18.4.7 Key Developments
18.4.8 SWOT Analysis
18.5 Mylan
18.5.1 Key Facts
18.5.2 Business Overview
18.5.3 Business Segmentation by Revenue 2013
18.5.4 Business Segmentation by Revenue 2011-2013
18.5.5 Geographical Segmentation by Revenue 2013
18.5.6 Business Strategy
18.5.7 Recent Developments
18.5.8 SWOT Analysis
18.6 Novartis AG
18.6.1 Key Facts
18.6.2 Business Description
18.6.3 Business Segmentation
18.6.4 Revenue by Business Segmentation
18.6.5 Revenue Comparison 2012 and 2013
18.6.6 Sales by Geography
18.6.7 Business Strategy
18.6.8 Key Developments
18.6.9 SWOT Analysis
18.7 Pfizer
18.7.1 Key Facts
18.7.2 Business Overview
18.7.3 Business Segmentation by Revenue 2013
18.7.4 Business Segmentation by Revenue 2012 and 2013
18.7.5 Geographical Segmentation by Revenue
18.7.6 Business Strategy
18.7.7 Key Developments
18.7.8 SWOT Analysis
18.8 Sanofi SA
18.8.1 Key Facts
18.8.2 Business Description
18.8.3 Business Segmentation
18.8.4 Revenue by Business Segmentation
18.8.5 Revenue Comparison 2012 and 2013
18.8.6 Sales by Geography
18.8.7 Business Strategy
18.8.8 Key Developments
18.8.9 SWOT Analysis
18.9 Valeant Pharmaceuticals International
18.9.1 Key Facts
18.9.2 Business Overview
18.9.3 Business Segmentation by Revenue 2013
18.9.4 Business Segmentation by Revenue 2012 and 2013
18.9.5 Sales by Geography
18.9.6 Business Strategy
18.9.7 Key Developments
18.9.8 SWOT Analysis
19. Other Reports in this Series